Related Experiment Video

Updated: May 30, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Therapeutic rationale for mTOR inhibition in advanced renal cell carcinoma

Holleh D Husseinzadeh1, Jorge A Garcia

  • 1Department of Internal Medicine, Taussig Cancer Institute, Cleveland, Ohio, USA.

Current Clinical Pharmacology
|August 11, 2011
PubMed

Insights

Mammalian target of rapamycin (mTOR) inhibitors show limited efficacy in advanced renal cell carcinoma (RCC) treatment, with minimal impact on tumor burden. Further research is exploring novel compounds targeting the PI3K/AKT pathway.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Mammalian target of rapamycin (mTOR) inhibitors are used for advanced renal cell carcinoma (RCC).
  • Their rationale involves inhibiting tumor cell proliferation and angiogenesis.
  • Clinical data on mTOR inhibitors in RCC shows mixed results.

Purpose of the Study:

  • To evaluate the clinical utility of mTOR inhibitors in advanced RCC.
  • To assess the efficacy of sequential VEGF and mTOR inhibition.
  • To explore novel therapeutic strategies targeting the PI3K/AKT pathway.

Main Methods:

  • Review of existing clinical data for Temsirolimus and Everolimus in advanced RCC.
  • Analysis of outcomes in patients treated with sequential VEGF and mTOR inhibitors.
  • Discussion of emerging research on PI3K/AKT pathway inhibitors.

Main Results:

  • Temsirolimus offers survival benefits in a subset of RCC patients but has minimal effects on tumor burden and progression-free survival (PFS).
  • Everolimus's utility in refractory settings is questionable, with outcomes potentially similar to sequential VEGF inhibitors.
  • Combination therapy of mTOR and VEGF inhibitors resulted in excessive toxicities without significant efficacy gains.

Conclusions:

  • Current mTOR inhibitors have limited clinical utility in advanced RCC.
  • The role of mTOR as a primary driver after VEGF inhibition requires further investigation.
  • Novel inhibitors targeting the PI3K/AKT pathway represent a promising future direction for RCC treatment.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...